Systemic complement activation levels in Stargardt disease.
Patty P A DhoogeEsmee H RunhartCatherina H Z LiCorrie M de Kat AngelinoCarel B HoyngRenate G van der MolenAnneke I den HollanderPublished in: PloS one (2021)
Systemic complement levels were not elevated in STGD1 patients compared to age and sex matched controls and was not associated with STGD1 severity. Considering the continued absent proof of a systemic contribution of the complement system to RPE loss in STGD1 patients, we hypothesize that complement activation in STGD1 is more likely a local process. In light of upcoming complement-targeted therapies, further studies are needed that measure complement levels in the eye of STGD1 patients.